射出分数の改善と心不全におけるダパグリフロジンの効果
Sara R O Siqueira1, Maria A Pabon1, Muthiah Vaduganathan1
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JACC. Heart failure
|August 20, 2025
まとめ
ダパグリフロジンは,エジェクション分数の改善に関係なく,改善されたエジェクション分数 (HFimpEF) で心不全を効果的に治療します. HFimpEFの患者は,LVEF ≥60%であっても,残留リスクに直面し,ダパグリフロジンから利益を得ます.
科学分野:
- 心臓病科
- 薬理学について
背景:
- 心臓機能不全の患者 (HFimpEF) はあまり研究されていません.
- これらの患者は,一貫して高いLVEFを持つ患者と同様の残留リスクに直面します.
- 改善されたLVEFの予後と治療への影響は不明である.
研究 の 目的:
- LVEFの改善度がHFimpEFの予後に影響するかどうかを調べる.
- LVEFの改善がHFimpEFにおけるダパグリフロジンの治療効果を変化させるかどうかを判断する.
主な方法:
- DELIVER試験のHFimpEFサブセットの分析
- ベースラインのLVEFとプライマリアウトカム (HF悪化またはCV死亡) の関連性を調べる.
- LVEFの改善がダパグリフロジンの治療反応を変化させるかどうかを評価する.
主要な成果:
- 患者1,151人がHFimpEFを示し,発症時のLVEF値は変化した.
- ダパグリフロジンは,すべてのLVEFグループで一貫してプライマリアウトカムリスクを低下させた.
- LVEFの改善とダパグリフロジンの有効性との間に有意な相互作用はありません (P=0. 19).
結論:
- LVEFの改善度に関係なく,Dapagliflozinの有効性と安全性はHFimpEF患者で一貫しています.
- LVEF ≥60%を達成した患者は,依然として重大な臨床イベントのリスクに直面しています.
- ダパグリフロジンは,HFimpEF患者にとって一貫した利点を提供します.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434